Boston Scientific drops plans to sell pain unit

Bloomberg has reported that Boston Scientific has abandoned its plans to auction off its neuromodulation business, which it had hoped to sell for up to $2 billion. Sources say companies interested in a deal were looking to pay $1 billion to $1.5 billion for the pain treatment division--much less that Boston Sci was asking. Article

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.